close

Clinical Trials

Date: 2011-01-20

Type of information: Results

phase: 2

Announcement: results of a further analysis of the large randomized Phase II OPUSa study

Company: Merck Serono, a Merck KGaA company (Germany)

Product: Erbitux (cetuximab)

Action mechanism:

IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR)

Disease:

KRAS wild-type metastatic colorectal cancer (mCRC)

Therapeutic area: Cancer - Oncology

Country:

Trial details:

A further analysis of the large randomized Phase II OPUSa study demonstrating an association between early tumor shrinkage and long-term median overall survival (OS) of more than 2 years for patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with Erbitux® (cetuximab) plus FOLFOX standard chemotherapy. This correlation was not seen in the chemotherapy-alone arm of the study.1 The study will be presented at the annual Gastrointestinal (GI) Cancers Symposium of the American Society of Clinical Oncology (ASCO).
This latest analysis shows that the majority of patients (69%) with KRAS wild-type mCRC demonstrated tumor shrinkage of 20% or more in the first 8 weeks of 1st line treatment with Erbitux and FOLFOX. These patients experienced a long-term median OS of 26.2 months. Patients treated with FOLFOX chemotherapy alone whose tumors shrank by 20% or more in the same period (46%) experienced median OS of only 21.8 months.
These results support recent findings from the Phase III CRYSTALb trial, which found that early tumor shrinkage achieved with Erbitux in combination with FOLFIRI standard chemotherapy led to a long-term median OS of 2.4 years (28.3 months).

Latest news:

Is general: Yes